MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager

Statement of Purpose
Guidelines for Authors
Editorial Board

Recent Issues

September 2010


An Update on Activated Protein C (Xigris) In the Management of Sepsis

Although human activated protein C (APC) has been used for years in patients with severe sepsis, trials have shown a lack of efficacy for the product and an increased incidence of bleeding. As a result, further study is needed to determine which patients are appropriate candidates for APC therapy.
Cesar Alaniz, PharmD

Drug Class Review

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes

Sitagliptin (Januvia) and saxagliptin (Onglyza) provide another option for type-2 ­diabetes. However, clinicians should consider the cost, the potential for hypoglycemia, and the modest efficacy associated with these agents.
Rolee Pathak, PharmD, RPh, BCPS; and Mary Barna Bridgeman, PharmD, RPh

Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States

Part 2: Regulatory and Safety Concerns and Proposed Governmental Policy Changes with Respect to Dietary Supplements

Despite the lack of data from trials of dietary supplements, reports of interactions with drugs are increasing. Proposed changes would enhance the FDA’s authority.
C. Lee Ventola, MS

Meeting Highlights

American Diabetes Association

Topics include sitagliptin (Januvia and Janumet), a combination tablet (Tribenzor), and an ­investigational agent (GFT505).
Walter Alexander

Pharmaceutical Approval Update

IncobotulinumtoxinA (Xeomin), indicated for cervical dystonia and blepharo- spasm, and ulipristal acetate (ella), an emergency contraceptive, are discussed.
Marvin M. Goldenberg, PhD, RPh, MS



It Takes a Village

It may take a village to help the nearly 73 million Americans with hypertension. A report from the Institute of Medicine recommends ways to reduce risks, improve medication adherence, and increase funding for prevention and wellness programs.
David B. Nash, MD, MBA

Medication Errors

‘Smart Pumps’ Are Not Smart On Their Own

Even though infusion pumps might be “smart,” they are useless unless clinicians take appropriate safety measures.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Drug Ads on TV and Radio May Need to Be More Explicit about Risks to Consumers

The FDA is trying to figure out how to force drug companies to state the risks of their drugs more clearly and conspicuously in TV and radio ads.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, product recalls, and industry updates.

Drug Forecast

Liraglutide (Victoza)

The First Once-Daily Incretin Mimetic Injection for Type-2 Diabetes

Liraglutide (Victoza), a once-daily incretin mimetic injection for type-2 diabetes
Sylvia H. Jackson, PharmD, CDE, MEd; Tonya S. Martin, PharmD, CGP, MAEd; Jocelyn D. Jones, PharmD, BCPS; David Seal, PharmD, MS; and Frank Emanuel, PharmD